Physician profile
Eric J Shakespeare
NPI 1225291198
$6,551.25
in general payments reported to CMS, 2019-2025
41 companies · $21.33 in 2025
The $21.33 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $540 · 2021: $641 · 2022: $1,909 · 2023: $2,044 · 2024: $671 · 2025: $21.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,188.76 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,180.13 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $564.16 | 2019-2024 | |
| Insmed, INC. | $551.83 | 2019-2023 | Arikayce |
| Harmony Biosciences LLC | $338.77 | 2021-2024 | Wakix |
| Philips North America LLC | $337.89 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $262.97 | 2019-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $222.74 | 2020-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $194.09 | 2020-2024 | Aralast, Glassia |
| Amgen INC. | $148.86 | 2021-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.82 | 2019-2021 | |
| Grifols USA, LLC | $109.76 | 2022-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $100.51 | 2019-2023 | Yupelri |
| Mallinckrodt Enterprises LLC | $91.68 | 2019 | |
| Axsome Therapeutics, INC. | $88.37 | 2022-2023 | Sunosi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shakespeare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.